Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

DELAFLOXACIN

Anionic fluoroquinolone antibiotic

ANTI-INFETCTIVE

CURRENT DEVELOPMENT PHASE: ABSSSI and CABP

preclinicl
phase i
phase ii
phase iii
pre-registration
post-registration

DELAFLOXACIN (CABP)


DELAFLOXACIN (ABSSSI)

Delafloxacin is an anionic fluoroquinolone (FQ) antibiotic, with a good safety profile, active against both Gram positive and negative bacteria, including Methicillin-resistant Staph. aureus (MRSA) and FQs resistant strains.

Based on the clinical results, delafloxacin could be an excellent treatment option for patients with comorbidities, at higher risk of infections by difficult-to-treat microorganisms, like MRSA and multi resistant Gram negative strains, which cause recurrent infections, poor patient outcomes and higher use of healthcare resources.

During the clinical development, delafloxacin demonstrated a good safety and tolerability profile, with improved characteristics in comparison to other antibiotics of this class (absence of QT-prolongation and phototoxicity).

In 2018, a marketing authorization application for the first indication of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) has been submitted to EMA and a global phase III registrational study in hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) has been completed.

To date, the clinical development of delafloxacin includes a phase IIIb clinical trial in ABSSSI started in 2019 and involving about 70 European clinical centers.

VISIT OUR CLINICAL TRIALS DATABASE

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more